Adding a yearly liquid biopsy to standard cancer screenings could substantially cut advanced-stage diagnoses but give only a modest boost to early detection rates, according to a new simulation study. The study, published in Cancer, estimated that — in over 10 years — annual screening with a multicancer early detection (MCED) test could lead to a 45% reduction in stage IV diagnoses of 14 cancers among Americans aged 50-84.